AboutOpen 2020-08-08T07:17:46+00:00 Lucia Steele Open Journal Systems <p>This open access journal publishes peer reviewed articles on clinical studies, real world evidence data, reviews, point of views, case series, and single clinical cases. The journal aim and scope encompasses clinical medicine, pharmacy, healthcare technology and other healthcare related disciplines with a focus on innovation in healthcare and policy. Articles may be in English, French, Italian and Spanish</p> Kidney Diseases: Challenges and Opportunities of the Third Millenium 2020-08-08T07:17:45+00:00 Antonio Bellasi Biagio Di Iorio Luca Di Lullo 2020-03-09T15:35:17+00:00 ##submission.copyrightStatement## A Budget impact analysis of pegfilgrastim biosimilar in the treatment of febrile neutropenia in Italy 2020-08-08T07:17:46+00:00 Roberto Ravasio Lorenzo Antonuzzo Marco Danova Paolo Pronzato <p class="abstract"><strong>Introduction:</strong> Granulocyte-colony stimulating factors (G-CSFs) can significantly reduce the risk of febrile neutropenia (FN) among certain patients receiving chemotherapy. FN is associated with significant clinical and nonclinical complications. At present, the patent protection of pegfilgrastim (Neulasta®) has expired, and a biosimilar (Ziextenzo®) has been approved. Since the biosimilar price is expected to be lower as compared with the originator’s, the present Drug Budget Impact analysis tries to evaluate whether and how much profitable the biosimilar availability will be for the Italian NHS, in terms of cost containment (savings).<br><strong>Methods and Results:</strong> The model time horizon extends to five years. The initial overall number of treatments with pegfilgrastim is estimated based on the number of pegfilgrastim packages (assuming a recommended dose of 6 mg is administered after each cytotoxic chemotherapy) and kept constant in time. The model assumes that, year by year, the number of treatments with the originator will partly switch to the biosimilar (according to an uptake rate assumed). The results show that the availability of the biosimilar would provide an €6.4 million cumulated savings to the NHS in the five years.<br><strong>Conclusions:</strong> According to the present analysis, the availability of the biosimilar would generate cumulated savings (in five years) as high as €6.4 million for the Italian NHS.&nbsp;</p> <p class="abstract">(HTA &amp; Market Access)</p> 2020-03-02T00:00:00+00:00 ##submission.copyrightStatement## Words for pharma: a quantitative and qualitative analysis on vision, mission and values of multinational pharma companies. 2020-08-08T07:17:45+00:00 Giulio Zuanetti Francesca Giorgia Colombo Carlotta Galeone <p><strong>Introduction</strong>: Pharma companies deal with the same important challenges that humans face: to grow and stay healthy. The crucial role of pharma companies in preserving health would suggest that they might rank highly in the reputation indexes. However, this does not seem to be the case. Our aim was to collect, cluster and analyse the words used by pharma companies in their mission, vision and value statements as a base to identify areas of improvement in their corporate communication.</p> <p><strong>Methods</strong>: A total of 97 multinational pharma companies were selected based on their size and presence within major markets. Mission, vision and company values were captured from company websites and analysed. Word clouds were built to analyse the frequency of words in the statement. The influence of company size and location was also analysed.</p> <p><strong>Results</strong>: Most companies (90.7%) have a mission and 54.6% have a clearly stated vision statement, 71.4% mention values. “Life/lives” “patients”, “innovative”, “people/persons” are the most frequently used words. “Innovation” and “integrity” are by far the most common values, followed by “respect”, “ethics”, “responsibility” and “passion”. References to healthcare professionals, access to treatment and sustainability, open science, transparency and care for the environment are more scanty.</p> <p><strong>Conclusions</strong>: Most, but not all, pharma companies provide comprehensive statements focussing mostly on the innovation and its impact on patients. Topics such as role of health care professionals, economic sustainability and care for the environment are rarely listed. An in-depth analysis of their alignment with key needs and trending topics is warranted to further engage customers and build reputation and value.</p> 2020-04-30T13:16:55+00:00 ##submission.copyrightStatement## A cost-minimization analysis of MD-Knee versus hyaluronic acid in patients with knee osteoarthritis 2020-08-08T07:17:44+00:00 Alberto Migliore Roberto Ravasio <p class="abstract"><strong>Introduction:</strong> The administration by injection of hyaluronic acid (HA) for 3-5 weeks is effective in the treatment of patients with knee osteoarthritis (OA). Other products for intra-articular use have been recently introduced for the treatment of OA. Among these, a medical device, MD-Knee, produced by Guna S.p.A.; this study aims to estimate the cost-minimization of MD-Knee versus HA in the treatment of knee osteoarthritis.</p> <p class="abstract"><strong>Methods and Results:</strong> We performed a cost-minimization analysis (CMA). The CMA was conducted from the perspective of the Italian National Health Service (iNHS). Only direct medical costs (MD-Knee and HA) were considered. We performed a sensitivity analysis to test the robustness of the results. The mean 6-months cost per patient was € 75,00 with MD-Knee and € 185,00 with HA.</p> <p class="abstract"><strong>Conclusion:</strong> From the Italian National Health Service’s perspective, MD-Knee appears to be the cost-saving therapeutic option compared with HA in the treatment of patients with knee osteoarthritis.</p> 2020-06-12T00:00:00+00:00 ##submission.copyrightStatement## Pronation Technique in ARDS Patients 2020-08-08T07:17:44+00:00 Raffaele Di Fenza Hedwige Gay Martina Favarato Isabella Fontana Roberto Fumagalli <p class="abstract">In severe acute respiratory distress syndrome (ARDS), characterized by the ratio of arterial partial pressure of oxygen over fraction of inspired oxygen (P/F) less than 150 mm Hg, pronation cycles are the only intervention that showed improved survival, in combination with protective ventilation. The physiological advantages of performing pronation cycles, such as the improvement of oxygenation, better tidal volume distribution with increased involvement of dorsal regions, and easier drainage of secretions, overcome the possible complications, that is, endotracheal tube occlusion or misplacement, pressure ulcers, and brachial plexus injury. However, the incidence of complications is dramatically lower in intensive care units with expertise, adopting prone positioning in daily practice.</p> <p class="abstract">In this video we are proposing step by step an easy and ergonomic technique to perform pronation maneuvers in patients with severe ARDS. Recent literature suggests that a high percentage of these patients are treated without undergoing pronation cycles.</p> <p class="abstract">The main purpose of this video is to help increase the number of intensive care units worldwide commonly performing pronation cycles in patients that have indications to be pronated, in order to decrease healthcare burden and costs directly caused by ARDS.</p> <p class="abstract">Proper intensive care unit staff training is fundamental in minimizing the risks associated with the maneuver for both patients and operators; and diffusion of a safe technique encouraging the operators is the second main purpose of this video.</p> <p><a href="" target="_blank" rel="noopener"><img src="/public/site/images/lsteele/2159_f1_750.png"></a></p> <p><em>(This video was recorded before the COVID-19 outbreak)</em></p> 2020-07-15T00:00:00+00:00 ##submission.copyrightStatement##